An interesting stock that came up in some of our conversations today is Protalix BioTherapeutics, Inc. (NYSE:PLX). At current price of $0.31, the shares have already lost -0.01 points (-5.71% lower) from its previous close of $0.32. Should you buy or avoid them? The stock sets an active trading volume day with a reported 484654 contracts so far this session. PLX shares had a relatively better volume day versus average trading capacity of 1.1 million shares, but with a 0.15 billion float and a 28.85% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for PLX stock indicates that the average analyst price target is $2.05 per share. This means the stock has a potential increase of 561.29% from where the PLX share price has been trading recently which is between $0.3 and $0.36. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $1.1. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $3.
During the recent trading session for Protalix BioTherapeutics, Inc. (NYSE:PLX), the company witnessed their stock rise $0.06 over a week and surge $0.07 from the price 20 days ago. When compared to their established 52-week high of $0.6, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 01/02/19. The recent low of $0.17 stood for a -49.12% since 10/14/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0 is also allocated to the stock. Since the beta is less than one, it implies that the stock is less volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for PLX is set at $2.05, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Protalix BioTherapeutics, Inc., the two-week RSI stands at 64.19. This figure suggests that PLX stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current PLX readings is similarly very revealing as it has a stochastic reading of 75.17% at this stage. This figure means that PLX share price today is being oversold.
Technical chart claims that Protalix BioTherapeutics, Inc. (PLX) would settle between $0.36/share to $0.39/share level. However, if the stock price goes below the $0.3 mark, then the market for Protalix BioTherapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.27 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.04. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Rodman & Renshaw lifted target price for shares of PLX but were stick to Buy recommendation for the stock in their opinion released on April 17. The price target has been raised from $4 to $5. Rodman & Renshaw, analysts launched coverage of Protalix BioTherapeutics, Inc. (NYSE:PLX) stock with a Buy recommendation, according to their flash note issued to investors on April 04. Analysts at Jefferies released an upgrade from Hold to Buy for the stock, in a research note that dated back to April 23.
PLX equity has an average rating of 2.32, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 2 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 2 analysts rated Protalix BioTherapeutics, Inc. (NYSE:PLX) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Protalix BioTherapeutics, Inc. (PLX)’s current-quarter revenues are projected to climb by nearly 24.1% to hit $12.85 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 45.9% from $34.24 million to a noteworthy $49.94 million. At the other end of the current quarter income statement, Protalix BioTherapeutics, Inc. is expected to see its adjusted earnings surge by roughly 50% to hit $-0.02 per share. For the fiscal year, PLX’s earnings are projected to climb by roughly 22.2% to hit $-0.14 per share.